FUJIFILM Corporation Announces Results from Phase II Clinical Trial of "T-817MA" in Patients with Alzheimer's Disease in the United States
FUJIFILM Corporation (TOKYO: 4901) (President: Kenji Sukeno) announced that the company’s Alzheimer’s Disease drug “T-817MA,” did not meet its primary study endpoints of cognition or global clinical function in its Phase II clinical trial conducted in the United States on patients with mild to moderate Alzheimer’s Disease (AD). There were no significant differences in secondary outcomes. In exploratory analyses, change of the cerebrospinal fluid (CSF) biomarker phospho-tau (p-Tau) benefited from the higher dose treatment while hippocampal*1 volumes decreased less in the lower doses group with statistical significance. Post hoc analyses also suggested T-817MA treatment with shorter duration of illness and symptoms was associated with better cognitive outcomes with statistical significance. Fujifilm will review the results of the Phase II clinical trial with regulatory authorities including FDA (U.S. Food and Drug Administration) and will take necessary steps toward further development including Phase III clinical trial of this compound.
A pre-clinical research, led by Dr. Rudolph Tanzi, Joseph P. and Rose F.
Kennedy Professor of Neurology at Harvard Medical School, and Vice-Chair
of Neurology at Massachusetts General Hospital, revealed that T-817MA
acts on microglia*2
that have a risk gene for AD and promotes
the clearance of amyloid-β (Aβ).
These results suggest that T-817MA may act on p-Tau and Aβ, major causal substances in AD.
AD’s main symptoms are abnormalities in cognitive functions, including
memory. It is believed that abnormality of neurological functions in AD
manifests as a result of Aβ protein deposits (senile plaques) in the
brain. The progression of the disease has strong association with the
formation of abnormal assemblies caused by hyperphosphorylation and
fibrillization of tau proteins, found in the axons of nerve cells
(neurofibrillary tangle), synapse*3
loss and atrophy of the
brain including hippocampus.
The number of people suffering from dementia is estimated to be 44 million around the world. The number is projected to increase to 76 million by 2030 with the aging of the world population. Over half of these dementia cases suffer from AD, and the trend is set to continue.
AD drugs currently available on the market include acetylcholinesterase inhibitors, such as donepezil hydrochloride. As these drugs address the deficit in neurotransmission to give temporary improvement to the patients' symptoms, there is an unmet need for a new class of therapies to treat AD.
T-817MA is an AD drug discovered by the Fujifilm Group company, Toyama Chemical. It has potent neuroprotective effect and promotes neurite outgrowth through the activation of sigma receptors*4 , demonstrating strong efficacy in animal models. Fujifilm is committed to further accelerating the development of T-817MA under possible partnerships, and contributing to resolving social challenges through the delivery of innovative pharmaceutical products.
|*1||Hippocampus is a region of the cerebrum, associated with memory. AD causes neuronal loss, which results in hippocampal atrophy.|
|*2||Microglia are a type of glia cells, which are component of the central nervous system. Microglia provide immune defense in the brain, while also being involved in repairing abnormal neural cells, and eliminating the aggregated Aβ. At the same time, excessively activated microglia are known to play a role in neuro-degeneration in the central nervous system.|
|*3||Synapse is a structure connecting neurons, allowing them to pass electrical signals to convey information between them.|
|*4||Sigma receptors are protein that exists on the membrane of endoplasmic reticulum in cells, and have the function of mitigating neuro-degeneration in the central nervous system.|
For enquiries on information in this media release, contact:
Kana Matsumoto, +81 3-6271-2000
Corporate Communications Division
Pharmaceutical Products Division
TEL +81 3-6271-2171
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
HCL-TECHNOLOGIES16.8.2018 21:04 | pressemeddelelse
Manchester United Shoots for Success with a “Digital Experience Platform” Powered by HCL
IBC16.8.2018 19:43 | pressemeddelelse
4K 4Charity Fun Run Announces Open Registration for IBC2018
AIAS/D.I.C.E.-CANNES16.8.2018 16:03 | pressemeddelelse
2018 D.I.C.E. Cannes Announced Round 3 Speakers
GN-HEARING16.8.2018 15:02 | pressemeddelelse
GN Hearing and Google Announce Partnership to Bring Direct Mobile Streaming from Android Devices to Hearing Aids
CA-GUIDEWIRE-SOFTWARE16.8.2018 14:57 | pressemeddelelse
Zurich Expands Global Use of Guidewire InsurancePlatform with Selection of Guidewire Cyence Risk Analytics
CA-SCIENTIST.COM16.8.2018 14:08 | pressemeddelelse
Scientist.com Named One of America’s Ten Fastest-Growing Private Companies by Inc. Magazine
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum